All News
Filter News
Found 239 articles
-
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
SpringWorks Therapeutics, Inc. announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
12/27/2022
SpringWorks Therapeutics, Inc. announced that the Company has completed the submission of a New Drug Application to the United States Food and Drug Administration for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.
-
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
11/22/2022
SpringWorks Therapeutics, Inc. today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET.
-
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
11/8/2022
ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.
-
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/3/2022
SpringWorks Therapeutics, Inc. reported third quarter financial results for the period ended September 30, 2022 and provided an update on recent company developments.
-
Tyra Biosciences Announces Planned Chief Financial Officer Transition
11/2/2022
Tyra Biosciences, Inc. announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
-
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
11/1/2022
Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX).
-
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
9/29/2022
SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors.
-
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
9/10/2022
SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, are being presented as a late-breaking oral presentation during a Presidential Symposium at the European Society for Medical Oncology Congress 2022.
-
SpringWorks, Eli Lilly, EMD Serono and Mirati released data ahead of the European Society of Medical Oncology (ESMO) 2022 Meeting in Paris.
-
SpringWorks announced the expansion of its partnership with GlaxoSmithKline to develop nirogacestat in combination with GSK's Blenrep for relapsed or refractory multiple myeloma.
-
SpringWorks Therapeutics Announces $225 Million Private Placement Financing
9/7/2022
SpringWorks Therapeutics, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 8,625,520 shares of its common stock at a price per share of $26.01 in a private placement transaction.
-
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
9/7/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (LSE/NYSE: GSK) for nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSK’s antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
-
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.
-
Combination Cancer Therapy Clinical Trials Report 2028
8/23/2022
Kuick Research Report Gives Comprehensive Clinical & Commercial Opportunity Insights More Than 600 Combination Cancer Drugs In Clinical Trials
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
8/19/2022
SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology Congress 2022.
-
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
8/9/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended June 30, 2022.
-
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8/8/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.